A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors

Glial tumors with oligodendroglial components are considered chemo-responsive. Forty newly diagnosed patients (11 anaplastic oligodendrogliomas [OD] and 29 anaplastic oligoastrocytomas [OA]) were enrolled into this multicenter, open-label, single-arm Phase II trial of first-line temozolomide (200 mg...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Gan, Hui K., Rosenthal, Mark A., Dowling, Anthony, Kalnins, Renate, Algar, Elizabeth, Wong, Nicholas, Benson, Angela, Woods, Anne-Marie, Cher, Lawrence
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2010
Témata:
Clinical Investigations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2940620/
https://ncbi.nlm.nih.gov/pubmed/20406900
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nop065
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky